Fairfield, Bush & Co’s BioMarin Pharmaceuticals BMRN Stock Holding History

Fairfield, Bush & Co’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-3,900	Closed	-$338K	–	149
2023 Q2	$338K	Buy	+3,900	New	+$367K	0.09%	121
2020 Q3	–	Sell	-2,000	Closed	-$247K	–	146
2020 Q2	$247K	Buy	+2,000	New	+$199K	0.09%	126
2016 Q1	–	Sell	-2,791	Closed	-$292K	–	137
2015 Q4	$292K	Buy	+2,791	New	+$291K	0.1%	115
2015 Q3	–	Sell	-1,996	Closed	-$273K	–	142
2015 Q2	$273K	Sell	1,996 -214	-10%	-$26.5K	0.08%	143
2015 Q1	$275K	Sell	2,210 -910	-29%	-$96.4K	0.08%	142
2014 Q4	$282K	Hold	3,120	–	–	0.08%	144
2014 Q3	$225K	Buy	+3,120	New	+$205K	0.06%	160

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fairfield, Bush & Co's BMRN Position: Q3 2023 in Review

Fairfield, Bush & Co sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2023, closing a stake of 3,900 shares — an estimated $338K sold.

Fairfield, Bush & Co first reported a position in BMRN in Q3 2014 and held it in 7 quarters. The position peaked at $338K in Q2 2023. 519 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

Fairfield, Bush & Co reported no remaining BioMarin Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Fairfield, Bush & Co sold 3,900 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $338K.
Fairfield, Bush & Co first reported a position in BioMarin Pharmaceuticals in Q3 2014 and held it in 7 quarters.
Fairfield, Bush & Co's BioMarin Pharmaceuticals position peaked at $338K in Q2 2023.
519 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on Fairfield, Bush & Co's 13F filing for Q3 2023, filed 15 Nov 2023.